Ribavirin 200 mg Tablets Under Non-Fasting Conditions

Completed · Phase 1

Conditions studied: Healthy

In brief

The objective of this study is to compare the relative bioavailability of ribavirin 200 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of COPEGUS™ 200 mg tablets (Roche) in healthy, adult, non-smoking, females (who are unable to become pregnant) under non-fasting conditions.

Key facts

Study ID
NCT00835536
Run by
Teva Pharmaceuticals USA
People needed
27
Starts
2003-09-01
Expected to finish
2003-10-01
Last updated by the study team
2024-08-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.